Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

MLA

DiGiovanna MP, et al. “Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 from the Cancer and Leukemia Group B.” Journal of Clinical Oncology, vol. 26, no. 14, May 2008, pp. 2364–72. EBSCOhost, https://doi.org/10.1200/JCO.2007.13.6580.

APA

DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD, DiGiovanna, M. P., Stern, D. F., Edgerton, S., Broadwater, G., Dressler, L. G., Budman, D. R., & Henderson, I. C. (2008). Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B. Journal of Clinical Oncology, 26(14), 2364–2372. https://doi.org/10.1200/JCO.2007.13.6580

Chicago

DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, et al. 2008. “Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 from the Cancer and Leukemia Group B.” Journal of Clinical Oncology 26 (14): 2364–72. doi:10.1200/JCO.2007.13.6580.